Table 3 Direct and non-direct costs variability intra country per patient according to phase of the disease and lymphocytes level (€ 2010)
From: Economic impact of HIV/AIDS: a systematic review in five European countries
Total healthcare costs | Spain (n* = 9) | Germany (n* = 3) | France(n* = 4) | Italy (n* = 17) | United Kingdom (n* = 15) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | MEAN | SD | MIN | MAX | n | MEAN | SD | MIN | MAX | n | MEAN | SD | MIN | MAX | n | MEAN | SD | MIN | MAX | n | MEAN | SD | MIN | MAX | |
According to phase of the disease (**) | |||||||||||||||||||||||||
Asymptomatic phase | 1 | 8.547,53 | - | - | - | 0 | - | - | - | - | 0 | - | - | - | - | 1 | 2.173,9 | - | - | - | 5 | 1.4991,73 | 3.493,29 | 10.571,45 | 18.290,76 |
Symptomatic phase | 1 | 10.173,81 | - | - | - | 0 | - | - | - | - | 0 | - | - | - | - | 0 | - | - | - | - | 5 | 19.222,25 | 4.437,73 | 12.131,42 | 22.945,24 |
AIDS phase | 2 | 11.032,38 | 1.058,39 | 10.272,01 | 11.768,99 | 0 | - | - | - | - | 0 | - | - | - | - | 1 | 15.182,96 | - | - | - | 5 | 42.968,55 | 12.487,71 | 23.155,18 | 53.241,22 |
According to lymphocytes level (CD4 cells) | |||||||||||||||||||||||||
CD4s < 200 | 0 | - | - | - | - | 0 | - | - | - | - | 0 | - | - | - | - | 3 | 19.252,63 | 5.840,26 | 15.182,96 | 25.944,39 | 3 | 49.326,37 | 6.250,58 | 42.117,73 | 53.241,22 |
200 < CD4s < 500 | 3 | 9.922,42 | 750,11 | 8.849,42 | 10.272,01 | 3 | 32.109,62 | 6.960,48 | 26.650,64 | 39.041,96 | 1 | 13.396,55 | - | - | - | 2 | 12.227,88 | 2.062,68 | 9.670,24 | 13.059,63 | 9 | 21.445,86 | 9.572,81 | 11.889,08 | 45.811,29 |
CD4s > 500 | 0 | - | - | - | - | 0 | - | - | - | - | 0 | - | - | - | - | 3 | 6.399,34 | 2.369,71 | 2.173,9 | 10.363,14 | 0 | - | - | - | - |